The longevity drugs everyone chases, graded on the trials, not the hype.
Rapamycin, Low-Dose Naltrexone, Semaglutide, Tirzepatide, Retatrutide, Metformin, SGLT2 inhibitors, Acarbose and RIMSO-50. We grade them the same way we grade everything: on human randomized trials, on the endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. that was actually measured, in the population it was actually measured in. Animal lifespan data and observational Research that watches what people already do rather than assigning a treatment. It can show that two things travel together, not that one causes the other. signals do not move a grade here.
The honest headline Two of these nine earn an A, and only for cardiometabolic or renal disease, not for longevity in healthy people. Semaglutide and SGLT2 inhibitors have replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. hard-endpoint trials in patients who already have that disease. RIMSO-50 holds B, Low-Dose Naltrexone, Tirzepatide, Retatrutide and Acarbose hold C and Rapamycin and Metformin hold D. None of the nine has shown a longevity benefit in healthy adults, because no trial has asked. Tap any drug to see exactly why.